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Background: While extensive evidence suggests that the economic recession has had far reaching effects on many
economic sectors, little is known regarding its impact on prescription drug utilization. The purpose of this study is
to describe the association between state-level unemployment rates and retail sales of seven therapeutic classes
(statins, antidepressants, antipsychotics, angiotensin-converting enzyme [ACE] inhibitors, opiates, phosphodiesterase
[PDE] inhibitors and oral contraceptives) in the United States.
Methods: Using a retrospective mixed ecological design, we examined retail prescription sales using IMS Health
Xponent™ from September 2007 through July 2010, and we used the Bureau of Labor Statistics to derive
population-based rates and mixed-effects modeling with state-level controls to examine the association between
unemployment and utilization. Our main outcome measure was state-level utilization per 100,000 people for each
class.
Results: Monthly unemployment levels and rates of use of each class varied substantially across the states. There
were no statistically significant associations between use of ACE inhibitors or SSRIs/SNRIs and average
unemployment in analyses across states, while for opioids and PDE inhibitors there were small statistically
significant direct associations, and for the remaining classes inverse associations. Analyses using each state as its
own control collectively exhibited statistically significant positive associations between increases in unemployment
and prescription drug utilization for five of seven areas examined. This relationship was greatest for statins (on
average, a 4% increase in utilization per 1% increased unemployment) and PDE inhibitors (3% increase in utilization
per 1% increased unemployment), and lower for oral contraceptives and atypical antipsychotics.
Conclusion: We found no evidence of an association between increasing unemployment and decreasing
prescription utilization, suggesting that any effects of the recent economic recession have been mitigated by other
market forces.
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The recent economic recession has heightened
awareness regarding the effects of unemployment
on health care utilization and health outcomes. There
are a variety of causal pathways and effects that are pos-
sible. For example, rising unemployment may lead to
increased rates of illness, including hypertension [1],* Correspondence: galexand@jhsph.edu
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reproduction in any medium, provided the orhypercholesterolemia [2], and other risk factors for car-
diovascular disease [3]. Increased unemployment has
also been associated with increased practice of deleteri-
ous health behaviors, such as smoking [4], heavy drink-
ing [5], and reduced amounts of physical activity [6].
These mitigating factors may contribute to increased
health care utilization. By contrast, individuals may re-
duce their health care spending and utilization through
an “income effect” or “insurance effect” [7,8]. While
COBRA does blunt the immediate impact of new un-
employment on insurance status, a prolonged recessionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thus increasing potential gaps in coverage. Use of
recommended preventive services such as colonoscopy
may concurrently decline [9]. Such decreases in
utilization might be particularly evident when examining
prescription drug use, since prescription drugs are
widely used, linked with the delivery of ambulatory care,
and the out-of-pocket costs for these therapies can be
considerable.
Although little is known regarding how the recent
economic recession has affected prescription drug
utilization, several studies have examined the effects of
the recession on other components of the health care
sector (Table 1). For example, the number of uninsured
nonelderly Americans increased by 5.6 million between
2007 and 2009 [10], and over a quarter of Americans
reported reducing their routine medical care use during
this recession [11]. Over the same period, deductibles,Table 1 Select examples of studies examining the association
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these decreases may occur not only for non-essential
treatments but also for essential medications such as in-
sulin, thiazides and furosemide [15]. Patients with low
incomes, multiple chronic health problems or no pre-
scription drug coverage may be particularly susceptible
to such “cost-related non-adherence” [16], although
there are a number of other factors that mediate these
associations as well [17]. Despite the insights from these
studies, they focus on a specific policy change among a
selected population, rather than a general deterioration
in the economic climate such as has accompanied the
recent economic recession.
We examined the association between state unemploy-
ment rates and retail prescription drug use over a period
of thirty-five-months. We focused on the use of seven
therapeutic classes - statins, antidepressants, antipsycho-
tics, Angiotensin-converting enzyme [ACE] inhibitors,
opiates, phosphodiesterase (PDE) inhibitors, and oral
contraceptives - that differ in terms of their indications,
target population and importance of consistent use. We
hypothesized a priori that increasing unemployment
would be associated with increasing use of some ther-
apies such as oral contraceptives, believing that un-
planned pregnancy would be even more carefully
avoided in times of limited resources as suggested by
prior studies [18]. On the other hand, we also pre-
dicted a decrease in use of other therapies such as
PDE inhibitors and statins that are used for “lifestyle”
or asymptomatic chronic conditions, as these medica-
tions may be deemed less essential from the patient’s
perspective when choosing between these therapies
and other important everyday commodities [19].
Meanwhile, the use of psychotropic medications was
predicted to increase with unemployment, as economic
hardship has previously been associated with poor
mental health [20]. In addition to examining the asso-
ciation between unemployment rates and medication
use, our data also allowed for us to examine variation
in rates of prescription utilization across states and
over time.Methods
Study design and state unemployment data
We used a mixed ecological design for our retrospective
analysis, focusing on the association between local eco-
nomic recession and outcome measures of prescription
drug utilization both across states and within states over
time. We collected state-level monthly unemployment
rates from 2007 to 2010 from the U.S. Bureau of Labor
Statistics [21]. This data served as a primary indicator of
the degree to which a specific state had experienced eco-
nomic hardship due to the recession.Data on prescription drug utilization
We used the IMS Health XponentTM database in order
to derive information about prescription drug sales.
These data, which have been previously described
[22,23], provide a highly representative sample of nation-
wide pharmaceutical dispensing in the United States,
using records from over 38,000 of the estimated 57,000
retail stores (more than a 70% sample), 119 of the 327
existing mail service pharmacy outlets, and 820 of the
estimated 3,000 long-term care pharmacies. XponentTM
includes both new and refilled prescriptions issued daily
from each of these dispensaries, with data aggregated for
stratification by geographic region, patient age, patient
gender, patient copayment, and method of payment, in-
cluding cash payment.
From this data we acquired state-level monthly esti-
mates of retail dispensed prescription drug utilization
across the therapeutic classes of interest from September
2007 to July 2010. Our inclusion of seven therapeutic
areas allowed us to examine the primary association of
interest for drugs that differed along a number of im-
portant dimensions, including: (1) use on an as-needed
vs. standing basis, (2) use for psychiatric vs. non-
psychiatric illness, (3) use for symptomatic vs. non-
symptomatic conditions, and (4) use for chronic disease
vs. use for conditions generally treated with therapies
regarded as “life-style medications”. Our retail dispensed
prescription data also included sociodemographic vari-
ables that allowed for stratified analyses with respect to
patient sex and age. We merged these data with publicly
available population estimates provided by the U.S. Bur-
eau of the Census and derived from the Current Popula-
tion Survey to calculate state-level rates of prescription
drug utilization.
Analysis
We first used the IMS Health XponentTM data and
population estimates from the Census Bureau to exam-
ine variation in the rates of prescription use per 100,000
individuals. Next, following Gibbons et al., we used
mixed-effects Poisson regression [24] and state-level
control variables to decompose the overall unemploy-
ment rate effects into between-state (state mean un-
employment rate) and within-state (monthly deviation
from the state mean unemployment rate) effects [25]
while conditioning on common factors affecting pre-
scribing behavior. We treated the within-state effect as a
random effect in the model to permit state-level vari-
ation in the associations between relative changes in un-
employment rates and state-level prescription rates. This
modeling approach not only allows us to differentiate
states which already had higher levels of unemployment
prior to the recession (i.e. Michigan) from states who
had lower levels, but also allows us to estimate a
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ment and drug utilization, capturing how this absolute
economic deprivation affects drug utilization. Our
within-state estimates then gauge how variation in rela-
tive economic deprivation within a state, associated
with the recession, relates to drug utilization. Whereas
our methods remove annual and quarterly temporal pat-
terns in drug utilization, this approach does not remove
potential confounding due to other well-characterized
temporal patterns in both drug utilization and un-
employment (e.g., calendar effects, autoregressive “mem-
ory” across quarters, or oscillations).
We derived empirical Bayes estimates of the state-
specific effects [24]. The estimated coefficients for our
mixed-effects Poisson regression models are reported in
Table 2 as incidence rate ratios (IRRs). Otherwise
known as rate multipliers, IRRs indicate the relative im-
pact of a covariate on a reference incidence rate, here
represented by the estimated intercept (which reports
the incidence rate of drug utilization per 100,000 indivi-
duals). An IRR of exactly 1.0 indicates that change in a
covariate has no impact, while an IRR of 0.75 indicates
that a one unit increase of the covariate is associated
with a 25% lower (0.75 times lower) rate of use com-
pared to the base incidence rate, and an IRR of 1.25
would indicate a 25% higher (1.25 times higher) rate of
use compared to the base incidence rate. Models
adjusted for covariates are depicted in Additional file 1:
Appendix Table S2.
Since rates of prescription drug utilization change over
time based on secular and seasonal trends, all models
controlled for these trends by including dummy vari-
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BIC = Bayesian Information Criterion, a measure of model fit; UnempDev = Deviatio
SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reupas reference). We included sex, age bracket, year and
season as dummy control variables. Thus, typically, the
base rate of utilization represents utilization per 100,000
males, who were between 20 and 64 years old, and who
filled a prescription during July through September
2008. Owing to the demographic-specific nature of some
drug classes, when drug utilization for a particular com-
bination of sex and/or age bracket was particularly low
(less than 1% of other combinations) that sex and/or age
bracket was removed from analysis. For example, we
excluded individuals less than 20 years of age in analyses
of statins and ACE inhibitors, and we excluded women
from the analyses of PDE inhibitors.
We performed a variety of sensitivity analyses to
examine whether our findings would differ based on our
analytic approach. First, we repeated our analyses after
limiting our population to individuals less than 65 years
of age who paid for prescriptions with cash. We rea-
soned that these subjects may be more likely to manifest
decreased prescription utilization with rising unemploy-
ment rates. Second, we conducted a similar sensitivity
analysis focusing on only those who were commercially
insured and under 65 years of age. Third, we incorpo-
rated a lag interval of three months for analysis to
examine whether there was an association between a
state’s unemployment rate and subsequent rates of drug
utilization. Finally, we repeated analyses without our
covariates to determine whether a simpler model would
produce substantively similar results. Comparison to
models with our covariates suggested that our covari-
ates had a statistically significant and policy relevant at-
tenuating effect, thus we included them in the final
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1: Appendix Table S2.
n from State Mean Unemployment; ACE = Angiotensin-converting enzyme;
take inhibitor; PDE = phosphodiesterase.
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Variation in unemployment and prescription utilization
There was substantial variation in state level monthly
unemployment during each year (Figure 1). For example,
during the fourth quarter of 2007 (2007Q4), unemploy-
ment rates varied from 2.8% to 7.3%, with a mean of
4.4% and standard deviation of 1.0%. As the recession
continued, the mean level of and variance in unemploy-
ment trended higher (mean 8.7% and standard deviation
of 2.1% in 2010Q1).
Rates of prescription utilization also varied consider-
ably across the therapeutic areas examined. For example,
the average rate of opioid use per 100,000 people during
2008 was approximately 5109, as compared with more
moderate rates of use of SSRIs/SNRIs (4115) and statins
(3929), and even lower rates of use of atypical antipsy-
chotics (966).
For most therapeutic areas, rates of use across the
states also varied substantially, with rates of use two- to
threefold greater in some states than others. For ex-
ample, average rates of atypical antipsychotic use varied
three-fold from 497 prescriptions per 100,000 residents
(Colorado) to approximately 1430 prescriptions per
100,000 residents (Connecticut and Massachusetts).
States that had higher utilization of one therapy gener-
ally had higher levels of utilization of other therapies as
well. In 39 states, the utilization of any two drug classes
exhibited a Pearson correlation of at least 0.6, with 22
states exhibiting a minimum correlation of 0.9.
Overall use of the therapies was greater among the
elderly than among non-elderly, although the elderly
only accounted for 25% of all use of the therapies exam-
ined. The proportion of all use that occurred among
those 65 years of age or greater was highest for statinsFigure 1 Monthly state-level unemployment rates, 2007–2010.(46%) and ACE inhibitors (42%), and lower for several of
the other classes examined.
Associations between unemployment and prescription
use across states
For 2 of the 7 therapeutic classes examined (ACE inhibi-
tors and SSRIs/SNRIs), there were no statistically signifi-
cant associations between the average state-level
unemployment and prescription utilization. In the case
of opioids and PDE inhibitors, there were small, statisti-
cally significant positive associations. For example, when
the average level of unemployment for a state increased
by 1% the number of opiate prescriptions per 100,000
people increased on average 2% (Table 2, “State Mean
Unemployment”). Similarly, when the average level of
unemployment for a state increased by 1% PDE inhibitor
utilization increased on average 1%. An inverse relation-
ship existed for statins, contraceptives and atypical anti-
psychotics, exhibiting decreases of 2%, 3% and 16%
respectively in the rate of utilization per 1% increase in
unemployment.
Associations between unemployment and prescription
use within states
Analyses of the association between prescription use and
change in unemployment relative to the state mean
allowed for each state to serve as its own control. Over-
all, states collectively exhibited statistically significant
positive associations between increases in unemploy-
ment and utilization of the therapies examined (Table 2,
“Deviation from State Mean Unemployment”). This as-
sociation was strongest for statins (on average, a 4% in-
crease in utilization per 1% increase in unemployment)
and PDE inhibitors (on average, a 3% increase in
utilization per 1% increase in unemployment), was
weaker for opiates, oral contraceptives, and atypical anti-
psychotics, and was not statistically significant in the
case of ACE inhibitors and SSRIs/SNRIs.
Figure 2A depicts these relationships for opiates. In 44
states, increased unemployment relative to the state
mean was associated with an increase in opiate
utilization. This varied from a high of approximately 5%
more prescriptions per 100,000 residents (Nebraska and
Ohio) to 0.1% more prescriptions (Washington) for each
1% increase in unemployment. Figures 2B, 2C, and 2D
depict the associations for other therapeutic areas. For
example, Figure 2B reflects the association between un-
employment and oral contraceptives use, demonstrating
a modest 0.6% average increase in the number of pre-
scriptions per 100,000 residents across all states for each
1% increase in unemployment. This average net increase
ranged from a 2.5% increase (North Dakota) to a 1.2%
decrease (Utah). Similar trends in the net association
were observed with atypical antipsychotics (Figure 2C)
Figure 2 A. Association between unemployment and state-level opioid utilization, 2007–2010. B. Association between unemployment
and state-level oral contraceptive utilization, 2007–2010. C. Association between unemployment and state-level atypical antipsychotic utilization,
2007–2010. D. association between unemployment and state-level pde inhibitor utilization, 2007–2010.
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in the direction of the relationship across states in the
latter case.Sensitivity analyses
These analyses comparing the findings for the popula-
tion of interest with those for the Medicare-insured
population, and with those for the cash-paying and com-
mercially insured populations under age 65, yielded no
change in the trends observed in the data. The incorpor-
ation of a lag interval also did not alter our main find-
ings or their substantive interpretation.Discussion
In this mixed ecological study analyzing prescription
drug use for each of the 50 states from September 2007
through July 2010, we observed wide variation in aggre-
gate utilization rates both across states and across the
drug classes of interest. Differences in utilization rates
across states were particularly large for statins and ACE
inhibitors, where some states had as much as five-fold
greater use, though each therapeutic class of interest
exhibited at least two- to threefold higher rates of use in
some states than others. Generally, higher utilization
rates in one class were accompanied by higher
utilization rates in the other classes. This across-state
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and did not change or diminish as a result of the reces-
sion. Ours is not the first study to suggest regional vari-
ation in prescription drug utilization [26-29], although
in contrast to most other work we examined a variety of
sources of payment as well as therapies differing along a
number of important clinical dimensions. Although our
mixed effects models suggested that the association be-
tween unemployment and prescription use varied re-
markably across states, we found no evidence of
substantial declines in prescription utilization associated
with the economic recession. Given the profound and
far-reaching effects of the recent economic recession in
a variety of economic sectors, these findings are import-
ant since little is known about how the recession has
been related to rates of drug utilization.
There are several reasons that may account for the ab-
sence of any discernible effect of the recession on rates
of prescription drug utilization. First, although our ana-
lyses included terms to account for seasonal and secular
trends in prescription drug utilization, we did not statis-
tically adjust for other market forces that may have
helped to attenuate any untoward effects of the reces-
sion on individuals’ access to prescription drugs. For ex-
ample, the rapid growth in the availability of generic
therapies, whose market share has increased from 63%
in 2006 to 78% in 2010 [30], may have helped to offset
decreases in use that would otherwise have been asso-
ciated with the economic hardship of the recession. In-
creasing availability of “$4 generic drug” programs
sponsored by major retailer and “big box” stores may
similarly have contributed to robust pharmaceutical sales
during this period [31]. Second, it is also possible that
most of the newly unemployed accounted for a relatively
small share of the market for prescription drugs and
thus that no effect of unemployment is seen, although
our findings were similar in sensitivity analyses limited
to those under 65 years of age with commercial insur-
ance or self-pay, and the elderly accounted for only ap-
proximately one-quarter of the entire market of
therapies examined. Third, there are a variety of path-
ways whereby economic recession may affect health and
health care utilization, and thus the absence of large
decreases in prescription utilization may reflect in part
changes such as anticipatory behavior [32] or increased
psychological, social, or physical stressors that offset
decreases that one might expect in prescription
utilization due to an insurance or income effect.
Our study has limitations and also leaves many ques-
tions unanswered. The greatest limitation of our report
is that our ecological analyses preclude an analysis of
important patient, provider, and health system character-
istics that may mediate or modify the associations that
we describe. Our investigation is one of states andmarkets, and thus should not be taken to suggest that
individuals have not modified their prescription drug
utilization as a result of economic hardship. Second, our
data consist of prescription sales rather than actual pre-
scription utilization, and despite our analysis of seven
therapeutic areas ranging from oral contraceptives to
atypical antipsychotics, it is possible that patterns of
utilization of other therapies differ. Finally, as our study
is ecological in nature, our findings are unable to pro-
vide any information with regard to the direction of
causation in the relationship between unemployment
and prescription drug utilization.Conclusion
Extensive evidence suggests that the economic recession
has had far reaching effects on many economic sectors,
including effects on rates of health insurance and health
care seeking behaviors in the United States. Despite this,
we found no substantial association between increasing
unemployment and decreasing prescription utilization,
suggesting that any untoward effects of the recent eco-
nomic recession have been buffered by other market
forces during the same period.Additional file
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